Evidence map›Paper›PMID 34164564›Full record

ArticleCellR4-- repair, replacement, regeneration, & reprogramming2020

Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).

G Lanzoni, E Linetsky, D Correa, R A Alvarez, A Marttos, K Hirani, S Messinger Cayetano, J G Castro, M J Paidas, J Efantis Potter and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CellR4-- repair, replacement, regeneration, & reprogramming, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

G LanzoniDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
E LinetskyDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
D CorreaDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
R A AlvarezUniversity of Miami Health System and Jackson Health System, Miami, FL, USA.
A MarttosDepartment of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
K HiraniDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
S Messinger CayetanoDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
J G CastroUniversity of Miami Health System and Jackson Health System, Miami, FL, USA.
M J PaidasUniversity of Miami Health System and Jackson Health System, Miami, FL, USA.
J Efantis PotterDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
X XuDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
M GlassbergDepartment of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
J TanOrgan Transplant Institute, Fuzhou General Hospital, Xiamen University, Fuzhou, China.
A N PatelDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.
B GoldsteinDepartment of Head and Neck Surgery and Communication Sciences, Duke University, Durham, NC, USA.
N S KenyonDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
D BaidalDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
R AlejandroDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
R ViannaDepartment of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
P RuizDepartment of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
A I CaplanDepartment of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
C RicordiDiabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Miami Transplant Institute · USUniversity of Miami · USUniversity of Miami Health System · USUniversity of Arizona · USDuke University · USJackson Health System · USUniversity of Utah · USXiamen University · CN

Funding

Strategies to Improve Long Term Islet Graft SurvivalU01DK070460 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI RICORDI, CAMILLO · 2004 to 2012
$11.6M
NIDDK NIH HHS U01 DK070460
6 · The paper itself

Abstract

The coronavirus SARS-CoV-2 is cause of a global pandemic of a pneumonia-like disease termed Coronavirus Disease 2019 (COVID-19). COVID-19 presents a high mortality rate, estimated at 3.4%. More than 1 out of 4 hospitalized COVID-19 patients require admission to an Intensive Care Unit (ICU) for respiratory support, and a large proportion of these ICU-COVID-19 patients, between 17% and 46%, have died. In these patients COVID-19 infection causes an inflammatory response in the lungs that can progress to inflammation with cytokine storm, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS), thromboembolic events, disseminated intravascular coagulation, organ failure, and death. Mesenchymal Stem Cells (MSCs) are potent immunomodulatory cells that recognize sites of injury, limit effector T cell reactions, and positively modulate regulatory cell populations. MSCs also stimulate local tissue regeneration via paracrine effects inducing angiogenic, anti-fibrotic and remodeling responses. MSCs can be derived in large number from the Umbilical Cord (UC). UC-MSCs, utilized in the allogeneic setting, have demonstrated safety and efficacy in clinical trials for a number of disease conditions including inflammatory and immune-based diseases. UC-MSCs have been shown to inhibit inflammation and fibrosis in the lungs and have been utilized to treat patients with severe COVID-19 in pilot, uncontrolled clinical trials, that reported promising results. UC-MSCs processed at our facility have been authorized by the FDA for clinical trials in patients with an Alzheimer's Disease, and in patients with Type 1 Diabetes (T1D). We hypothesize that UC-MSC will also exert beneficial therapeutic effects in COVID-19 patients with cytokine storm and ARDS. We propose an early phase controlled, randomized clinical trial in COVID-19 patients with ALI/ARDS. Subjects in the treatment group will be treated with two doses of UC-MSC (l00 × 10

Indexed as

Acute Respiratory Distress Syndrome (ARDS)Coronavirus Disease 2019 (COVID-19)Umbilical cord-derived mesenchymal stem cells (UC-MSCs)

Identifiers

PMID34164564
PMCPMC8218794
OpenAlexW3175274971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.